Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
GnRH receptor antagonist (Livzon)
- Development stage
- Preclinical
- Lead developer
- Livzon Pharmaceutical
- Modality
- Peptides, Small Molecules
- Administration
- Oral, Subcutaneous
01
Overview
This asset refers to a gonadotropin-releasing hormone (GnRH) receptor antagonist program under development by Livzon Pharmaceutical Factory. The drug is designed to treat hormone-sensitive conditions, such as endometriosis, uterine fibroids, and prostate cancer, by competitively binding to GnRH receptors in the pituitary gland. This action blocks the signaling of endogenous GnRH, leading to a rapid and reversible suppression of luteinizing hormone (LH) and follicle-stimulating hormone (FSH) secretion. Consequently, the production of ovarian estrogens in women and testicular testosterone in men is reduced to castrate levels. Unlike GnRH agonists, antagonists do not cause an initial hormonal surge (flare effect), providing immediate therapeutic benefit. The program includes both small molecule and peptide candidates, potentially including generic versions of established antagonists like relugolix or cetrorelix.
- Other names
- GnRH拮抗剂GnRH antagonist
02
Targets
GnRHR (Gonadotropin-releasing hormone receptor)
Beyond the preview
Go deeper on GnRH receptor antagonist (Livzon).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on GnRH receptor antagonist (Livzon).